Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, United States of America.
Sci Rep. 2019 Jan 14;9(1):114. doi: 10.1038/s41598-018-37128-y.
Tumor tissue mutational burden (TMB) has emerged as a promising predictive biomarker for immune checkpoint therapy. Measuring TMB from circulating tumor DNA (ctDNA) found in plasma is attractive in tissue-constrained indications. We compared the performance of two plasma-based commercial TMB assays including the effect of two different collection methods. Our findings suggest that the two plasma based TMB assays are highly correlated and they are also both correlated with a tissue-based TMB assay for relatively high TMB samples. The two collection methods are also found to be very comparable. Plasma-based TMB assays may be mature enough to be clinically useful in mCRPC and potentially other indications.
肿瘤组织突变负担（TMB）已成为免疫检查点治疗有前途的预测生物标志物。从血浆中发现的循环肿瘤 DNA（ctDNA）中测量 TMB 在组织受限的适应症中具有吸引力。我们比较了两种基于血浆的商业 TMB 检测方法的性能，包括两种不同采集方法的影响。我们的研究结果表明，两种基于血浆的 TMB 检测方法高度相关，并且它们与基于组织的 TMB 检测方法对于相对较高的 TMB 样本也相关。两种采集方法也被发现非常相似。基于血浆的 TMB 检测方法可能已经足够成熟，可以在 mCRPC 及其他潜在适应症中具有临床应用价值。
